30 September 2024: QScint awarded Phase II SBIR grant by NIH/NIBIB
Tucson, AZ - 30 September 2024 - QScint Imaging Solutions LLC (QScint), a world-leader in the production of real-time, quantitative alpha- and beta-particle imagers for radiopharmaceutical therapy research and digital autoradiography in both academia and industry today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the NIH and NIBIB to develop “Novel Isotopic Spectroscopy Imaging Tools for Advancing Targeted Alpha Cancer Therapies”.
Under the grant, QScint will develop its previously-demonstrated approach to identifying specific alpha- and beta-emitting isotopes in list-mode image data into a commercial product. The technology will allow users of QScint’s iQID imaging systems to create “isotopic images” of radiotracer distributions in real time. This “isotopic spectroscopy” will be an invaluable, unprecedented tool to help scientists understand the distribution of parent and progeny isotopes and their fates in tissue.
Remarking on the award, Dr. Brian Miller, President of QScint noted: “We’re pleased and honored that the SBIR’s panel of scientific reviewers have recognized the potential of this technology to provide greater insights into how candidate radiotherapy molecules behave through time at the near-cellular level. We believe that isotopic spectroscopy will improve the efficiency of development pipelines for radiopharmaceuticals and targeted alpha therapies, as well as help identify potential new uses for molecules in development. Beyond its scientific value, this grant will help QScint continue to grow in its role of providing fundamental research tools to scientists developing the next generation of targeted cancer treatments.”
This press release is regarding National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health Award Number R44EB035459.
